WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 20, 2014--
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical
device provider, today announced that it will present at the Leerink
Swann 2014 Global Healthcare Conference at the Waldorf Astoria Hotel in
New York on Wednesday, February 12, 2014. Management is scheduled to
present at 11:30 a.m. Eastern Time.
A live audio webcast and replay of the presentation will be available
for 30 days following the presentation at www.atricure.com.
About AtriCure, Inc.
Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy Ablation System is the first and only device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in
patients undergoing certain open concomitant procedures. AtriCure’s
AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely
implanted device for LAA management worldwide. The company believes
cardiothoracic surgeons are adopting its ablation and LAA management
devices for the treatment of Afib and reduction of Afib related
complications such as stroke. Afib affects more than 5.5 million people
Source: AtriCure, Inc.
Andy Wade, Vice President and Chief Financial
Lynn Pieper, 415-202-5678